Redx Pharma (REDX) Share Price, News & Analysis

Company Overview

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 15 to 15
• 52-Week Range: N/A
• Volume: 1.42 million shs
• Average Volume: 707,637 shs
• Market Capitalization: £58.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REDX Stock Analysis - Frequently Asked Questions

How were Redx Pharma's earnings last quarter?

Redx Pharma Plc (LON:REDX) posted its quarterly earnings results on Monday, November, 19th. The company reported ($7.00) EPS for the quarter, missing the consensus estimate of ($6.50) by $0.50.

How do I buy shares of Redx Pharma?

Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Redx Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Redx Pharma investors own include AutoZone (AZO), Barclays (BARC), Salesforce (CRM), Digital Globe Services (DGS), Intel (INTC), Legal & General Group (LGEN) and OptiBiotix Health (OPTI).

Company Calendar

• Last Earnings: 11/19/2018
• Today: 7/20/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:REDX
• CIK: N/A
• Web: redxpharma.com
• Phone: +44-151-7064747
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): GBX (0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£33.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -180.80%
• Return on Assets: -43.95%

Debt

• Debt-to-Equity Ratio: 527.00
• Current Ratio: 1.11
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: £4.20 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 5.23
• Book Value: GBX 1 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 388,990,000
• Free Float: N/A
• Market Cap: £58.35 million
• Optionable: Not Optionable
• Beta: -0.53